# Release Readiness Verdict — Step 12

## Decision
**No-Go (blocking defects present)**

## Evidence Baseline
- Automation execution summary: **38/43 passed, 3 failed, 2 skipped**  
  Source: `05_automation/reports/summary/summary.md`
- Failed tests are confirmed server-side defects (not suppressed):
  - `TC-PRESCRIPTIONS-NEG-002` → **KAN-49**
  - `TC-BILLING-NEG-002` → **KAN-50**
  - `TC-DOCTORS-NEG-002` → **KAN-51**
- Additional confirmed exploratory defect:
  - Clinically implausible dosage accepted (`BUG-ONCO-004`) → **KAN-52**

## Patient-Safety First Risk Statement
1. **Critical patient-safety blocker**: server accepts negative prescription quantity (`KAN-49`).  
   This can allow unsafe medication orders and dosage interpretation errors.
2. **High-risk prescribing control gap**: implausible dosage text accepted (`KAN-52`).  
   This can allow unsafe instructions to be persisted without fail-safe controls.
3. **High financial integrity blocker**: negative billing unit price accepted (`KAN-50`).
4. **Medium master-data integrity blocker**: negative doctor experience accepted (`KAN-51`).

## Skip/Block Notes
- Cross-user access isolation API test skipped because `ODOO_SECONDARY_USER` / `ODOO_SECONDARY_PASSWORD` are not configured.
- Billing-total consistency positive API check skipped when no qualifying data record was available in that run context.

## Release Condition for Re-evaluation
Release can be reconsidered only after:
1. Server-side validation fixes for KAN-49, KAN-50, KAN-51, KAN-52 are deployed.
2. Defect retest confirms failures no longer reproduce.
3. Full regression rerun shows no blocking patient-safety or data-integrity failures.

## Final Verdict
**No-Go** until all blocking defects above are fixed and verified.
